Windlas Biotech consolidated net profit rises 10.59% in the December 2022 quarter

Windlas Biotech Ltd, Dynemic Products Ltd Partly Paidup, Coastal Corporation Ltd Partly Paidup and KPI Green Energy Ltd are among the other losers in the BSE’s ‘B’ group today, 25 October 2022.

Starlit Power Systems Ltd leads losers in ‘B’ group

Consolidated EBITDA came in at Rs13.8 crore in Q1FY23 as compared to Rs12.4 crore in Q1FY22.

Windlas Biotech posts single-digit growth numbers in Q1FY23; stock slips ~2%

Stocks in Focus on May 13: TaMo, L&T, SBI, Eicher Motors, Windlas Biotech & More

Windlas Biotech consolidated net profit rises 150.68% in the March 2022 quarter

Stocks in news: Reliance Industries, HCL Tech, Tata Communications, CRISIL, Cyient, Windlas Biotech, TVS Motor and more

Stocks in news: Reliance Industries, HCL Tech, Tata Communications, CRISIL and more

Shares of Windlas Biotech rose over 3 per cent amid a falling market today after its investor ICICI Prudential MF raised stake in the firm. The stock opened higher at Rs 262 against the previous close of Rs 261.60 on BSE. Windlas Biotech shares further zoomed 4.66 per cent to Rs 273.8 on BSE.

Windlas Biotech stock climbs over 4% after ICICI Prudential MF raises stake

Windlas Biotech shares zoomed 18.52 per cent to Rs 280 on BSE. Earlier, the stock opened 4.13 per cent higher at Rs 246 against the previous close of Rs 236.25.

Windlas Biotech stock zooms 18 per cent amid market crash, here’s why

Pearl Polymers Ltd, Ginni Filaments Ltd, Windlas Biotech Ltd and Magadh Sugar & Energy Ltd are among the other gainers in the BSE’s ‘B’ group today, 18 April 2022.

TCPL Packaging Ltd leads gainers in ‘B’ group

Windlas Biotech surged 12.34% to Rs 265.40 after the company concluded its European Union GMP Inspection carried out by National Institute of Pharmacy and Nutrition, Hungary for the Plant-IV situated at Dehradun with zero critical observations.

Windlas Biotech soars on zero observations at Dehradun unit; bags GMP certificate from SAHPRA

Windlas Biotech consolidated net profit declines 32.33% in the December 2021 quarter

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

The stock has a moderate number of red flags

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

The company provides pharmaceutical development services. It provides contract manufacturing services for pharmaceutical industrialists and also focuses on product development and manufacturing capabilities in generic products.